MANE
Veradermics, Inc
NYSE · Healthcare · Biotechnology · US
$143.85
+0.01%Oct 19, 2026, 18:00 UTC
Veradermics shares rose 6.98% to $116.42 on Monday after positive topline Phase 3 trial results were reported.
Source:Oct 19, 2026, 11:00 UTC
Veradermics announced positive topline results from Part A of its Phase 3 Study 304 evaluating oral VDPHL01 in more than 500 males with mild-to-moderate pattern hair loss.
Source:Oct 18, 2026, 22:00 UTC
Veradermics announced it will host an investor call and live webcast on October 19, 2026, at 8:00 a.m. ET to review Part A results from its Phase 3 Study 304 of VDPHL01.
Source:Aug 11, 2026, 11:30 UTC
Veradermics reported its financial results for the second quarter ended June 30, 2026.
Source:Jul 15, 2026, 17:47 UTC
Veradermics Incorporated released topline results from an open-label Phase 2 trial of its experimental oral hair loss drug VDPHL01 in women with mild-to-moderate pattern hair loss.